2. Search Result
Search Result
Results for "

radionuclides therapy

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

3

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10732
    DOTA-cyclo(RGDfK)

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-cyclo(RGDfK)
  • HY-139564
    DOTA Zoledronate

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .
    DOTA Zoledronate
  • HY-170779
    DOTA-NI-FAPI-04

    		FAP Cancer
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([ 68Ga]Ga/DOTA-NI-FAPI-04 and [ 177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .
    DOTA-NI-FAPI-04
  • HY-164589
    NOPO

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NOPO
  • HY-164653
    DOTAEt

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTAEt
  • HY-P10730
    DOTA-Lanreotide

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-Lanreotide
  • HY-164590
    BCN-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    BCN-NODAGA
  • HY-164599
    TA-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA
  • HY-P10731
    DOTA-NAPamide

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-NAPamide
  • HY-164594
    TA-DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA-GA
  • HY-164592
    DTPA-tetra(tBu)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA-tetra(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DTPA-tetra(tBu)ester
  • HY-W999782
    Propargyl-DOTA-tris(tBu)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Propargyl-DOTA-tris(tBu)ester
  • HY-164603
    3p-C-NOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NOTA
  • HY-164596
    THP(Bz3)-Glu

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz3)-Glu
  • HY-164654
    DOTA-PEG10-azide

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-PEG10-azide
  • HY-W999766
    Propargyl-NOTA(tBu)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    Propargyl-NOTA(tBu)2
  • HY-W586475
    Fluorescein-triazole-PEG5-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Fluorescein-triazole-PEG5-DOTA
  • HY-164591
    THP(Bz)3-NH2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz)3-NH2 is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz)3-NH2
  • HY-164593
    NH-CH2-CH2-DOTAM

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NH-CH2-CH2-DOTAM
  • HY-164656
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE

    		Drug-Linker Conjugates for ADC Cancer
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE
  • HY-164588
    NH2-PEG4-NODA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-NODA-GA
  • HY-159770A
    (S)-EB-FAPI-B2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .
    (S)-EB-FAPI-B2
  • HY-W873634
    TRAP

    TRAP-Pr

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
    TRAP
  • HY-132989
    Mal-Deferoxamine

    		Reactive Oxygen Species (ROS) Apoptosis Autophagy HIF/HIF Prolyl-Hydroxylase Akt Radionuclide-Drug Conjugates (RDCs) Cancer
    Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. .
    Mal-Deferoxamine
  • HY-W011118
    DTPA anhydride

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DTPA anhydride
  • HY-147057
    Rofapitide tetraxetan
    2 Publications Verification

    FAP-2286

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .
    Rofapitide tetraxetan
  • HY-106244A
    DOTATATE acetate
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE acetate
  • HY-106244
    DOTATATE
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE
  • HY-W755033
    NH2-PEG4-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-DOTA is a bifunctional, DOTA-type metal chelator. NH2-PEG4-DOTA can be conjugated with Dextran for quantitative analysis in the presence of a highly luminescent complex. NH2-PEG4-DOTA can also bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-DOTA
  • HY-164725
    FAPI-mFS

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-158125
    PSMA binder-2

    		PSMA Cancer
    PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-2
  • HY-173374
    DOTAGA-FAP-2286-ALB

    		FAP Drug Derivative Cancer
    DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .
    DOTAGA-FAP-2286-ALB
  • HY-100138
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)

    		Radionuclide-Drug Conjugates (RDCs) ADC Linker Cancer
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as 68Ga, 177Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
  • HY-158118
    Lys(CO-C3-p-I-Ph)-OMe

    		DNA-PK Cancer
    Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    Lys(CO-C3-p-I-Ph)-OMe

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: